The successful treatment of primary cardiac lymphoma with a dose-dense schedule of rituximab plus CHOP

Abstract

Primary cardiac lymphoma (PCL) is a rare and often fatal malignancy with a varied clinical presentation [1]. Despite the well-documented clinical course, there is little consensus on management of this lymphoma, including the best modality of medical imaging for diagnosis and monitoring [1]. We report the first case of the combination of rituximab and CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) (R-CHOP) given at 14-day intervals as successful therapy for PCL. We also highlight the integral role of cardiac magnetic resonance imaging (MRI) and ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) in guiding diagnosis, management and monitoring of this condition.